Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by fouremmon Mar 12, 2015 6:13pm
235 Views
Post# 23515953

RE:RE:RE:RE:RE:RE:RE:RE:I see the PPS heading over $2......

RE:RE:RE:RE:RE:RE:RE:RE:I see the PPS heading over $2......Just to be clear, I never meant to sound like I thought DM was stupid, just not as knowledgeable about markets as a public co CEO should be.  I have in the past thought he was a bit out of his element, although I think he has been much improved in the last while. I have talked to him a couple of times and he does seem down to earth and I think he truly believes in what he is doing.  He also has an excellent team.  I like the cocoon reference.  In general I'm not a big fan of consolidation either unless it serves a purpose, such as a NADAQ listing, and is attached to a meaningful change in the story.  RVX has had some very meaningful positive changes recently but at this rate I think the share price may take care of itself if the potential for a NASDAQ listing if it is in the cards.  Speaking of NASDAQ listings I've always thought one of the reasons that Zenith is headquartered in San Fransisco is that it is a hub of US biotech activity and a natural place to be for a NASDAQ listing when the time comes.  I think I've typed NASDAQ listing enough now so I'll quit.  Great day for RVX.
Bullboard Posts